CRVS
Corvus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Consensus Rating "Buy"
Significant Net Income Growth
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRVS
Corvus Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing immuno-oncology therapies to enhance the immune systems of patients with solid tumors and cancer
901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080
--
Corvus Pharmaceuticals, Inc., was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immunotherapeutic oncology programs designed to use the immune system to attack cancer cells. Since the start of operations in November 2014, four immuno-oncology programs have been built, three of which focus on the adenosine cancer axis regulating the immune response pipeline. The company's lead product candidate, CPI-444, A2A receptor adenosine, is an oral small molecule antagonist for immune checkpoints.
Earnings Call
Q1/2025
Estimate EPS-0.12
Actual EPS-0.13
Estimate Revenue--
Actual Revenue0
Corvus Pharmaceuticals' 2025 Q1 Earnings Call: Unraveling Contradictions on Dosing, Efficacy, and Combination Therapies
May 19,2025 05:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CRVS has released its 2025 Q1 earnings. EPS was reported at -0.13, versus the expected -0.12, missing expectations. The chart below visualizes how CRVS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
